Beatrice Mauro - Roche Holding Non-Executive Director
| RHHBY Stock | USD 30.54 0.70 2.24% |
Director
Prof. Dr. Beatrice Weder di Mauro is NonExecutive Director at Roche Holding AG since 2006. In addition, she acts as Member of the Audit Committee of the Company. She studied at Universitaet Basel, Department of Economics, where she gained a Doctorate degree in 1993. From 1993 until 1994, Prod. Dr. Weder di Mauro was PostDoctoral Research Fellow at the University of Basel. From 1994 until 1996, she was Economist at the International Monetary Fund, Washington D.C. From 1996 until 1997, Prof. Dr. Weder di Mauro was Economist at the World Bank, Washington D.C. From 1997 until 1998, she was Research Fellow at the United Nations University, Tokyo. From 1998 until 2001, she was Assistant Professor of Economics at the Universitae Basel. Since 2001, she was Professor of Economics at the University of Mainz and since 2004, Prof. Dr. Weder di Mauro was Member of the German Council of Economic Experts. She was Member of the Board of Macroeconomic Advisors of the Swiss Federation from 2002 until 2004. From 2001 until 2004, she was Member of the Scientific Advisory Board of the Institute for Economic Research in Hamburg. From 2002 until 2004, she was CoEditor of Applied Economics Quarterly in Berlin. Prof. Dr. Weder di Mauro is Member of the Supervisory Board of ERGO Insurance Group since 2005. Since 2003, she was Research Fellow at the Center For Economic Policy Research and since 2005, she was Member of the Steering Committee of the Group The Macroeconomics of Global Interdependence. She is Member of Committee on International Economics of the Verein fuer Socialpolitik since 2005. Prof. Dr. Weder di Mauro is Research Fellow at the Center for Financial Studies in Frankfurt since 1999, among others. since 2006.
| Age | 49 |
| Tenure | 18 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Khalil Barrage | Protagenic Therapeutics | 50 | |
| Brian Corvese | Protagenic Therapeutics | N/A | |
| Joshua Silverman | Protagenic Therapeutics | 47 | |
| Robert Stein | Protagenic Therapeutics | 65 | |
| Gregory Ekizian | Protagenic Therapeutics | 51 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Head of Group HR | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, General Counsel and Corporate Secretary | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, COO of Pharmaceuticals division | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, Chief Financial and IT Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, CEO and Executive Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 293.22 B | |||
| Shares Outstanding | 6.4 B | |||
| Shares Owned By Institutions | 1.27 % | |||
| Price To Earning | 17.56 X | |||
| Price To Book | 9.81 X | |||
| Price To Sales | 3.99 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding Ltd. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |